Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Huaren Pharmaceutical CoSZSE:300110 -1.03%55 FCF Yield % is 8.25 as of Aug. 26, 2026, which is 93% above its 10-year median of 4.28. GuruFocus rates SZSE:300110 with a GF Score™ of 55/100 and a GF Value™ of ¥3.13 (Fairly Valued). The stock has 8 warning signs investors should review. Among 1,003 Drug Manufacturers companies, Huaren Pharmaceutical Co ranks better than 84.05% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Huaren Pharmaceutical Co FCF Yield % Related Terms
Huaren Pharmaceutical Co FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Huaren Pharmaceutical Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Huaren Pharmaceutical Co FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Huaren Pharmaceutical Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Huaren Pharmaceutical Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Huaren Pharmaceutical Co (SZSE:300110) has a FCF Yield % of 8.25 as of Aug. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Huaren Pharmaceutical Co and its competitors. This is 93% above median its historical median of 4.28. According to the industry distribution chart, Huaren Pharmaceutical Co ranks #160 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 16%.
Is Huaren Pharmaceutical Co's FCF Yield % too high?
Huaren Pharmaceutical Co's current FCF Yield % of 8.25 is 93% above median its 10-year median of 4.28. The Drug Manufacturers industry median FCF Yield % is 0.66. Huaren Pharmaceutical Co's value of 8.25 is 1150% above this industry median. Based on the distribution chart, Huaren Pharmaceutical Co ranks #160 out of 1003 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Huaren Pharmaceutical Co has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Huaren Pharmaceutical Co's FCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Huaren Pharmaceutical Co ranks #160 out of 1003 companies for FCF Yield %. This places Huaren Pharmaceutical Co in the top 16% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.66. Huaren Pharmaceutical Co's value of 8.25 is 1150% above this benchmark. While the company's 10-year median is 4.28 vs. the industry median of 0.66, Huaren Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.66, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Huaren Pharmaceutical Co's current FCF Yield % of 8.25 is 1150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Huaren Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Huaren Pharmaceutical Co's current FCF Yield % is 8.25, which is 93% above median its own 10-year median of 4.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Huaren Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Huaren Pharmaceutical Co (SZSE:300110) is currently considered Fairly Valued. The stock's GF Value™ is ¥3.13, compared to a current price of ¥2.87 — trading 8.3% below its estimated fair value. The current FCF Yield % is 8.25, which is 93% above median its 10-year median of 4.28 and 1150% above the Drug Manufacturers industry median of 0.66. Huaren Pharmaceutical Co's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Huaren Pharmaceutical Co (SZSE:300110), the current FCF Yield % is 8.25 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Huaren Pharmaceutical Co (SZSE:300110) Overvalued in 2026?
Based on GuruFocus' analysis, Huaren Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥2.87 is trading 8.3% below its estimated GF Value™ of ¥3.13.
GuruFocus considers Huaren Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SZSE:300110:
FCF Yield %: 8.25 (93% above median its 10-year median of 4.28)
GF Value™: ¥3.13 vs. price of ¥2.87 (8.3% below fair value)
Industry Position: 1150% above the Drug Manufacturers median (#160 of 1003)
No single metric tells the full story. See the SZSE:300110 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Huaren Pharmaceutical Co Ltd is a China-based company engaged in the manufacture, and sale of non-polyvinyl chloride and Non-PVC large capacity preparations. Its categories of products include conventional infusion, therapy infusion, and nutrition infusion. The company distributes its products in domestic market, with Northeast China as its main market.
55GF Score
Get the complete analysis for SZSE:300110
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300110 has been successfully added to your 
